Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Analyst Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VIR Stock 12 Month Forecast
Average Price Target
$16.86
▲(188.21%Upside)
| Highest Price Target$31.00 | Average Price Target$16.86 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$5.5
Hold
-5.98%
Downside
Reiterated
07/18/25
Vir Biotechnology's overall stock score is primarily impacted by financial volatility with declining revenue and profitability. Despite a strong balance sheet, cash flow issues raise liquidity concerns. The earnings call offered positive strategic insights, supporting the score, but valuation challenges due to financial losses remain significant.
Raymond James
$12
Buy
105.13%
Upside
Initiated
07/11/25
Bank of America Securities
$12
Hold
105.13%
Upside
Reiterated
06/26/25
Leerink Partners
―
Buy
―
Reiterated
06/02/25
Needham
$14
Buy
139.32%
Upside
Reiterated
05/22/25
H.C. Wainwright
$110→$15
Buy
156.41%
Upside
Reiterated
05/20/25
TD Cowen
―
Buy
―
Reiterated
05/08/25
Barclays
$31
Buy
429.91%
Upside
Reiterated
05/08/25
Morgan Stanley
$20
Buy
241.88%
Upside
Reiterated
05/08/25
J.P. Morgan
$14
Hold
139.32%
Upside
Reiterated
05/07/25
Goldman Sachs
$28→$21
Buy
258.97%
Upside
Reiterated
04/16/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$5.5
Hold
-5.98%
Downside
Reiterated
07/18/25
Vir Biotechnology's overall stock score is primarily impacted by financial volatility with declining revenue and profitability. Despite a strong balance sheet, cash flow issues raise liquidity concerns. The earnings call offered positive strategic insights, supporting the score, but valuation challenges due to financial losses remain significant.
Raymond James
$12
Buy
105.13%
Upside
Initiated
07/11/25
Bank of America Securities
$12
Hold
105.13%
Upside
Reiterated
06/26/25
Leerink Partners
―
Buy
―
Reiterated
06/02/25
Needham
$14
Buy
139.32%
Upside
Reiterated
05/22/25
H.C. Wainwright
$110→$15
Buy
156.41%
Upside
Reiterated
05/20/25
TD Cowen
―
Buy
―
Reiterated
05/08/25
Barclays
$31
Buy
429.91%
Upside
Reiterated
05/08/25
Morgan Stanley
$20
Buy
241.88%
Upside
Reiterated
05/08/25
J.P. Morgan
$14
Hold
139.32%
Upside
Reiterated
05/07/25
Goldman Sachs
$28→$21
Buy
258.97%
Upside
Reiterated
04/16/25
Best Analysts Covering Vir Biotechnology
1 Month
xxx
Success Rate
8/21 ratings generated profit
Average Return
-6.58%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 38.10% of your transactions generating a profit, with an average return of -6.58% per trade.
3 Months
xxx
Success Rate
9/22 ratings generated profit
Average Return
-9.40%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.91% of your transactions generating a profit, with an average return of -9.40% per trade.
1 Year
2 Years
xxx
Success Rate
4/17 ratings generated profit
Average Return
-24.75%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 23.53% of your transactions generating a profit, with an average return of -24.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VIR Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
14
8
9
8
8
Buy
3
1
2
3
3
Hold
4
1
5
10
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
10
16
21
26
Each month's total comprises the sum of three months' worth of ratings.
VIR Financial Forecast
VIR Stock Forecast FAQ
What is VIR’s average 12-month price target, according to analysts?
Based on analyst ratings, Vir Biotechnology’s 12-month average price target is 16.86.
What is VIR’s upside potential, based on the analysts’ average price target?
Vir Biotechnology has 188.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VIR a Buy, Sell or Hold?
Vir Biotechnology has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
What is Vir Biotechnology’s price target?
The average price target for Vir Biotechnology is 16.86. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $31.00 ,the lowest forecast is $12.00. The average price target represents 188.21% Increase from the current price of $5.85.
The highest analyst price target is $31.00 ,the lowest forecast is $12.00. The average price target represents 188.21% Increase from the current price of $5.85.
What do analysts say about Vir Biotechnology?
Vir Biotechnology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of VIR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.